SpletShoreline Biosciences, Inc. (Shoreline) is a biotechnology company developing intelligently designed, allogeneic off-the-shelf, targeted cellular immunotherapies derived from induced pluripotent ... Splet12. apr. 2024 · SAN DIEGO, April 12, 2024 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today …
Huang Zhu - Vice President of Research - Shoreline ... - LinkedIn
Splet10. maj 2024 · Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells, or iPSCs, utilizing its proprietary iPSC-derived ... Splet14. apr. 2024 · Shoreline Biosciences, a California-based start-up specializing in iPSC-derived cellular immunotherapies for cancer and other serious diseases, announced it … cpt morgan mosby
Shoreline Biosciences and BeiGene Announce Strategic Worldwide
Splet07. nov. 2024 · Shoreline成立于2024年,总部位于加利福尼亚州圣地亚哥,致力于推动智能设计的同种异体即用型(off-the-shelf)、靶向和标准化iPSC衍生的NK和巨噬细胞免疫疗法,用于治疗癌症和其他严重疾病。 目前,该公司已建立一条NK细胞/巨噬细胞疗法候选药物管线。 iPSC衍生的细胞治疗技术平台 Shoreline的核心细胞治疗平台能生产出优化的、 … SpletThat is, while randomly integrated CARs seem to work well in iPSC-derived NK cells and T cells, this targeted insertion approach is likely needed for derivation of more functional iPSC-derived CAR-macrophages. Figure 1. Disclosures Kaufman: Qihan Biotech: Consultancy; VisiCell: Consultancy; Shoreline Bioscience: Current holder of stock Splet12. apr. 2024 · Shoreline presented two posters demonstrating its novel methodologies to produce clinical scale iPSC-derived iNK cells. Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production. Shoreline's methodology supports the production of phenotypically and functionally … distance from van alstyne tx to memphis tn